Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we talk about the midsummer chill in the biotech market here in my home town of San Diego. Also, we learn that it was FDA cancer chief Richard Pazdur’s intervention that contributed to the rejection of Replimune’s melanoma drug …
Read More »Readout Newsletter: Replimune, Gilead PrEP, Novartis
